drugset
drugset / Trial / NCT00759720

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

NCT00759720 ↗

Phase 3 Terminated 447 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of TAK-559, once daily (QD), combined with glyburide in treating Type 2 Diabetes.

Timeline

Start
2003-11
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IMIGLITAZAR Small molecule 16 mg Oral
Subject IMIGLITAZAR Small molecule 32 mg Oral
Comparator Glyburide Small molecule — Oral

Indications

diabetes mellitus